244
PROMs have been extensively studied in clinical trials. However, there is scar-
city of real world data on instruments used for PROMs. The real world data will
identify any feasibility issues related to PROM administration, data capture and
broad scale implementation [ 64 ]. Observational studies or national registries are
required to capture PROM data to study feasibility and other relevant issues on
PROM administration in clinical care.
PROM instruments can sometimes be too lengthy and diffi cult to administer in
routine clinical care. Shorter versions for such instruments need to be developed and
tested in clinical trials for routine use. Other measures such as GAQ are still in their
infancy and more clinical trials are required before they can be adopted into clinical
practice.
References
- Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diag-
nosis of gout. Rheum Dis Clin North Am. 2014;40(2):193–206. - Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2011;63(4):238–45.
- Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep.
2008;10(3):249–55. - Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open.
2012;2(1), e000282. - Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial
infarction. Arthritis Rheum. 2006;54(8):2688–96. - Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor?
Ann Rheum Dis. 2015;74(4):631–4. - Singh JA, Yang S, Strand V, Simon L, Forsythe A, Hamburger S, et al. Validation of pain and
patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum
Dis. 2011;70(7):1277–81. - Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported
outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38(7):1452–7. - Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of
life and physical function in patients with refractory chronic gout following treatment with
pegloticase: evidence from phase iii randomized controlled trials. J Rheumatol.
2012;39(7):1450–7. - Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying
antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care.
2008;14(4):234–54. - Valderas JM, Alonso J. Patient reported outcome measures: a model-based classifi cation sys-
tem for research and clinical practice. Qual Life Res Int J Qual Life Asp Treat Care Rehab.
2008;17(9):1125–35. - Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the
patient's perspective into drug development and communication: an ad hoc task force report of
the patient-reported outcomes (pro) harmonization group meeting at the food and drug admin-
istration, February 16, 2001. Value Health. 2003;6(5):522–31. - Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B, Mayo FDAP- ROCMG. Patient-
reported outcomes: conceptual issues. Value Health. 2007;10 Suppl 2:S66–75. - Patient Reported Outcome Measures Information System (PROMIS). Patient reported out-
comes (PROs). 2015. http://www.nihpromis.org/patients/PROs.
J. Singh and N. Shah